Key result
Beta-blockers are commonly prescribed antihypertensive medications among patients receiving hemodialysis, and the category contains agents with considerably variable dialyzability.
Why the study?
Should dialyzable β-blockers be used in patients receiving hemodialysis?
Should dialyzable β-blockers be used in patients receiving hemodialysis?
Answers are grounded in this paper and cite their sources.
This editorial discusses the pharmacokinetic considerations of using dialyzable versus non-dialyzable β-blockers in patients undergoing hemodialysis.
Dialyzability is a pharmacokinetic parameter that reflects the efficiency of drug withdrawal from the circulation by the filter of hemodialysis.1 Whether a drug is extensively cleared during hemodialysis is determined by its physicochemical characteristics and its overall pharmacokinetic profile.1 β-Adrenergic receptor blockers (β-blockers) are among the most commonly prescribed antihypertensive medications among patients receiving hemodialysis.2 The β-blocker category contains agents with considerably variable dialyzability.
No takes yet. Share an insight, caveat, or question.
Georgianos et al. (2022) conducted an editorial in Hemodialysis. Dialyzable β-Blockers was evaluated. Beta-blockers are commonly prescribed antihypertensive medications among patients receiving hemodialysis, and the category contains agents with considerably variable dialyzability.
Synapse has enriched 10 related papers. Consider them for comparative context: